Table 2. Characteristics of Patients with CML whose CD34+ Cells were Used for Testing Triptolide Sensitivity.

patient	source	blast %	treatment and responses at the time of sampling	Bcr-Abl mutation status	BC lineage
1	PB	59	resistant to or relapsed from various treatment including Interferon, imatinib, dasatinib, fludarabine+Ara-C bid, and intravenous homoharringtonine + imatinib	F317L	myeloid
2	PB	17	resistant to various therapies including Interferon + low dose Ara-C, imatinib, nilotinib, and dasatinib	wt	myeloid
3	PB	58	resistant to imatinib and nilotinib	F317L	lymphoid
4	PB	58	achieved short hematological remission with Idarubicin+Ara-C / imatinib but soon after had evidence of Ph+ chromosome, resistant to dasatinib and MK-0457	T315I	myeloid
5	BM	60	achieved hematological response with imatinib and dasatinib, achieved and then lost cytogenetic response to dasatinib, was on bosutinib	V299L	myeloid